Artelo Biosciences Expanding Use Of ART27.13 In Muscle Preservation For Glucagon-Like Peptide-1 Receptor Agonist Therapy Patients

Artelo Biosciences, Inc. (Nasdaq: ARTL) has announced a strategic expansion of its ART27.13 treatment to focus on muscle preservation in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonist therapy. The company is dedicated to developing therapies for individuals with cancer, pain, dermatologic, or neurological conditions.